Pancreatic Cancer Research

ResearcherNational Taiwan UniversityActive in the last 2 years

Bang‐Bin Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7058-1427; OpenAlex author ID A5060346234. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
22
Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 3 papers · 2022: 2 papers · 2023: none · 2024: 1 paper

Papers 9

  1. Adding-on nivolumab to chemotherapy-stabilized patients is associated with improved survival in advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00262-024-03821-3↗
  2. Maintenance therapy of low-dose nivolumab, S-1, and leucovorin in metastatic pancreatic adenocarcinoma with a germline mutation of MSH6: A case report. First author DOI 10.3389/fimmu.2022.1077840↗
  3. Case Report: Maintenance Nivolumab in Complete Responder After Multimodality Therapy in Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.3389/fimmu.2022.870406↗
  4. Preoperative sarcopenia is associated with poor overall survival in pancreatic cancer patients following pancreaticoduodenectomy. Last author DOI 10.1007/s00330-020-07294-7↗
  5. Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma. Co-author DOI 10.1080/2162402x.2021.1973710↗
  6. Metabolic Alterations in Pancreatic Cancer Detected by In Vivo 1H-MR Spectroscopy: Correlation with Normal Pancreas, PET Metabolic Activity, Clinical Stages, a… Last author DOI 10.3390/diagnostics11091541↗
  7. S-1-Associated Hypertriglyceridemia in a Patient With Pancreatic Adenocarcinoma. Co-author DOI 10.1200/jop.19.00204↗
  8. Multiparametric PET/MR imaging biomarkers are associated with overall survival in patients with pancreatic cancer. Co-author DOI 10.1007/s00259-018-3960-0↗
  9. Pancreatic cancer screening in different risk individuals with family history of pancreatic cancer-a prospective cohort study in Taiwan. Co-author PMID 28337383↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shih‐Hung Yang · 8 shared papers, 2017–2024 · strength 1.16
  2. Yu‐Wen Tien · 6 shared papers, 2018–2024 · strength 0.85
  3. Sung‐Hsin Kuo · 4 shared papers, 2020–2024 · strength 0.67
  4. Ting‐Chun Kuo · 3 shared papers, 2018–2022 · strength 0.41
  5. Ann‐Lii Cheng · 2 shared papers, 2021–2024 · strength 0.35
  6. Kun‐Huei Yeh · 2 shared papers, 2021–2024 · strength 0.35
  7. Li‐Yuan Bai · 2 shared papers, 2021–2022 · strength 0.31
  8. Yu‐Ting Chang · 3 shared papers, 2017–2021 · strength 0.29
  9. Ming‐Chu Chang · 3 shared papers, 2017–2021 · strength 0.29
  10. Yan‐Shen Shan · 1 shared paper, 2024 · strength 0.22
  11. Tiffany Ting‐Fang Shih · 2 shared papers, 2018–2021 · strength 0.22
  12. Mei‐Fang Cheng · 2 shared papers, 2018–2021 · strength 0.22
  13. Shang‐Hsuan Peng · 1 shared paper, 2022 · strength 0.20
  14. Chiun Hsu · 1 shared paper, 2022 · strength 0.19
  15. Yan-Chih Peng · 1 shared paper, 2021 · strength 0.16
  16. Tzu‐Pin Lu · 1 shared paper, 2021 · strength 0.16
  17. Chih‐Horng Wu · 2 shared papers, 2017–2018 · strength 0.15
  18. Chih-Kai Chang · 1 shared paper, 2021 · strength 0.14
  19. Hsing-Wu Chen · 1 shared paper, 2020 · strength 0.13
  20. Yung‐Ming Jeng · 1 shared paper, 2017 · strength 0.07
  21. Po‐Chin Liang · 1 shared paper, 2017 · strength 0.07
  22. I‐Shiow Jan · 1 shared paper, 2017 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.